Cell Therapeutics, Inc.

514 articles about Cell Therapeutics, Inc.

• 

  5-Member GO Therapeutics Inks $195 Million Deal with Roche

  10/2/2018

  GO Therapeutics, headquartered in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.

• Cell Therapeutics, Inc. Announces Change Of Name To CTI BioPharma Corp.

  5/30/2014

• Cell Therapeutics, Inc. To Present At The Jefferies and Co. 2014 Global Healthcare Conference

  5/29/2014

• Cell Therapeutics, Inc. Reports First Quarter 2014 Financial Results

  4/30/2014

• Cell Therapeutics, Inc. PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  4/29/2014

• Cell Therapeutics, Inc. To Report First Quarter 2014 Financial Results On April 29, 2014

  4/22/2014

• Cell Therapeutics, Inc. To Present At The 26th Annual ROTH Conference

  3/5/2014

• Cell Therapeutics, Inc. Reports Fourth Quarter And Full Year 2013 Financial Results

  3/5/2014

• Cell Therapeutics, Inc. Opens Enrollment For PERSIST-2 Phase 3 Trial Of Pacritinib For Patients With Myelofibrosis Who Have Low Platelet Counts

  3/3/2014

• Cell Therapeutics, Inc. Release: National Institute for Clinical Excellence (NICE) Publishes Final Guidance On PIXUVRI® (pixantrone)

  2/27/2014

• Cell Therapeutics, Inc. To Report Fourth Quarter And Full Year 2013 Financial Results On March 4, 2014

  2/25/2014

• Cell Therapeutics, Inc. Appoints Karen Ignagni To Board Of Directors

  2/3/2014

• Cell Therapeutics, Inc. Announces United Kingdom National Cancer Research Institute AML Cooperative Group Phase 2 Trial Evaluating Pacritinib For Patients With Relapsed FLT3 Positive Acute Myeloid Leukemia

  1/30/2014

• Cell Therapeutics, Inc. Announces GOG Completes Patient Enrollment In GOG-0212 Phase 3 Clinical Trial Of Paclitaxel Poliglumex (Opaxio™) As Maintenance Therapy In Ovarian Cancer

  1/28/2014

• Cell Therapeutics, Inc. Reaches Agreement To Reacquire Rights To Two Anti-Cancer Compounds

  1/13/2014

• Cell Therapeutics, Inc.'s PIXUVRI® Gets Good News From The UK

  1/7/2014

• FDA Lifts Hold On Studies Testing Cell Therapeutics, Inc.'s Cancer Drug Tosedostat

  1/2/2014

• Cell Therapeutics, Inc. Receives Remaining $5 Million Under Existing Loan Financing Agreement

  12/18/2013

• Cell Therapeutics, Inc. Release: Integrated Safety And Efficacy Analysis Of Phase 2 Clinical Trials Of Pacritinib In Patients With Myelofibrosis And Low Platelet Counts Presented At American Society of Hematology Annual Meeting

  12/9/2013

• Cell Therapeutics, Inc. And GKV-SV Reach Agreement On Pricing Of PIXUVRI® (pixantrone) In Germany

  12/4/2013